2003
DOI: 10.1007/s00403-003-0432-5
|View full text |Cite
|
Sign up to set email alerts
|

The lazaroid tirilazad is a new inhibitor of direct and indirect UVA-induced lipid peroxidation in human dermal fibroblasts

Abstract: Lipid peroxidation caused by oxidative stress within the tissue leads to destruction and dysfunction of cellular membranes. Human dermal fibroblasts in the skin are subject to constant photooxidative stress caused mainly by deeply penetrating UVA irradiation. Therefore, the membrane damage caused by this photooxidative stress may be a major promoter of photoaging and photocarcinogenic processes initiated and promoted by long-term UVA exposure of the skin. The oxidative destruction is counterbalanced by a compl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2004
2004
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 48 publications
0
2
0
Order By: Relevance
“…A concentration of 50 mM was chosen based on the fact that this is within the concentration range of compounds normally tested on fibroblasts [25][26][27]. Using the MTT assay, the viability of the cells treated with these compounds at 50 mM did not differ from that of the control (p > 0.05) (data not shown).…”
Section: Resultsmentioning
confidence: 96%
“…A concentration of 50 mM was chosen based on the fact that this is within the concentration range of compounds normally tested on fibroblasts [25][26][27]. Using the MTT assay, the viability of the cells treated with these compounds at 50 mM did not differ from that of the control (p > 0.05) (data not shown).…”
Section: Resultsmentioning
confidence: 96%
“…These findings stimulated the development of a group of glucocorticoid analogs, the 21‐aminosteroids (lazaroids), that specifically inhibit lipid peroxidation without glucocorticoid or mineralocorticoid activity, thereby avoiding the complications of GC therapy (42, 59). One representative of this class of drugs, tirilazad, has been shown to be neuroprotective (60) and to inhibit ultraviolet A–induced lipid peroxidation in human dermal fibroblasts (61). This drug is generally well tolerated; adverse reactions (such as local discomfort at the site of infusion and physical signs of local venous irritation), although commonly observed, are usually mild and transient.…”
Section: New Glucocorticoids In the Pipelinementioning
confidence: 99%